&nbsp;

HCTFP_Policy_EN.pdf

Apr 2023

Document

HCTFP_Policy_Fr.pdf

Apr 2023

High Risk Ontario Breast Screening Program FAQs for Healthcare Providers

Les fournisseurs de soins primaires sont le premier point de contact pour les femmes, les personnes trans et les personnes non binaires qui peuvent...

Document

H-YSM_GeneralFAQ.pdf

Jun 2023

Document

H-YSM_GeneralFAQ-FR.pdf

Jun 2023

Document

H-YSM_VolunteerTrainingResource_FR.pptx

Jun 2023

Regimen

MOGA

Cancer Type:

Hematologic,

Lymphoma - T-cell

Intent: Palliative

Funding:

New Drug Funding Program

Mogamulizumab - Relapsed or Refractory Mycosis Fungoides or Sezary Syndrome

, Collapse Show fewer tags

Drugs Used:

mogamulizumab

... Show more tags

Quick Link(s):

Regimen Monograph

May 2024

Document

HCP-Switching-Reference-Biologics-to-Biosimilar-Biologics.pdf

Jan 2024

Document

HCP-Switching-Reference-Biologics-to-Biosimilar-Biologics-FR.pdf

Jan 2024

Regimen

MFOLFOX6+PEMB+TRAS

Cancer Type:

Gastrointestinal,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab and Trastuzumab (Biosimilar) - First-line Treatment of Advanced HER2-Positive Gastric or Esophagogastric Junction Adenocarcinoma

New Drug Funding Program

Pembrolizumab and Trastuzumab (Biosimilar) - First-line Treatment of Advanced HER2-Positive Gastric or Esophagogastric Junction Adenocarcinoma

, Collapse Show fewer tags

Drugs Used:

Quick Link(s):

Regimen Monograph

Dec 2024

Regimen

MFOLFOX6+PEMB

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma